Charlotte Marie Pretzsch

Dr. Charlotte Marie Pretzsch


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2015 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
MKMartha D. Kaiser
Martha D. Kaiser
DYDaniel Y.-J. Yang
Daniel Y.-J. Yang
AVAvery C. Voos
Avery C. Voos
RBRandi H. Bennett
Randi H. Bennett
IGIlanit Gordon
Ilanit Gordon
KPKevin A. Pelphrey
Kevin A. Pelphrey
C-tactile (CT) afferents encode caress-like touch that supports social–emotional development, and stimulation of the CT system engages the insula and cortical circuitry involved in social–emotional processing. Very few neuroimaging studies have investigated the neural mechanisms of touch processing in people with autism spectrum disorder (ASD), who often exhibit atypical responses to touch. Using functional magnetic resonance imaging, we evaluated the hypothesis that children and adolescents with ASD would exhibit atypical brain responses to CT-targeted touch. Children and adolescents with ASD, relative to typically developing (TD) participants, exhibited reduced activity in response to CT-targeted (arm) versus non-CT-targeted (palm) touch in a network of brain regions known to be involved in social–emotional information processing including bilateral insula and insular operculum, the right posterior superior temporal sulcus, bilateral temporoparietal junction extending into the inferior parietal lobule, right fusiform gyrus, right amygdala, and bilateral ventrolateral prefrontal cortex including the inferior frontal and precentral gyri, suggesting atypical social brain hypoactivation. Individuals with ASD (vs. TD) showed an enhanced response to non-CT-targeted versus CT-targeted touch in the primary somatosensory cortex, suggesting atypical sensory cortical hyper-reactivity.

6 February 2019 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
CPCharlotte Marie Pretzsch
Charlotte Marie Pretzsch
JFJan Freyberg
Jan Freyberg
BVBogdan Voinescu
Bogdan Voinescu
DLDavid Lythgoe
David Lythgoe
JHJamie Horder
Jamie Horder
GMGráinne M. McAlonan
Gráinne M. McAlonan
There is increasing interest in the use of cannabis and its major non-intoxicating component cannabidiol (CBD) as a treatment for mental health and neurodevelopmental disorders, such as autism spectrum disorder (ASD). However, before launching large-scale clinical trials, a better understanding of the effects of CBD on brain would be desirable. Preclinical evidence suggests that one aspect of the polypharmacy of CBD is that it modulates brain excitatory glutamate and inhibitory γ-aminobutyric acid (GABA) levels, including in brain regions linked to ASD, such as the basal ganglia (BG) and the dorsomedial prefrontal cortex (DMPFC). However, differences in glutamate and GABA pathways in ASD mean that the response to CBD in people with and without ASD may be not be the same. To test whether CBD ‘shifts’ glutamate and GABA levels; and to examine potential differences in this response in ASD, we used magnetic resonance spectroscopy (MRS) to measure glutamate (Glx = glutamate + glutamine) and GABA+ (GABA + macromolecules) levels in 34 healthy men (17 neurotypicals, 17 ASD). Data acquisition commenced 2 h (peak plasma levels) after a single oral dose of 600 mg CBD or placebo. Test sessions were at least 13 days apart. Across groups, CBD increased subcortical, but decreased cortical, Glx. Across regions, CBD increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the DMPFC was significant. Thus, CBD modulates glutamate-GABA systems, but prefrontal-GABA systems respond differently in ASD. Our results do not speak to the efficacy of CBD. Future studies should examine the effects of chronic administration on brain and behaviour, and whether acute brain changes predict longer-term response.

15 November 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IGIlanit Gordon
Ilanit Gordon
AJAllison Jack
Allison Jack
CPCharlotte Marie Pretzsch
Charlotte Marie Pretzsch
BWBrent Vander Wyk
Brent Vander Wyk
JLJames F. Leckman
James F. Leckman
KPKevin A. Pelphrey
Kevin A. Pelphrey
Oxytocin (OT) has become a focus in investigations of autism spectrum disorder (ASD). The social deficits that characterize ASD may relate to reduced connectivity between brain sites on the mesolimbic reward pathway (nucleus accumbens; amygdala) that receive OT projections and contribute to social motivation, and cortical sites involved in social perception. Using functional magnetic resonance imaging and a randomized, double blind, placebo-controlled crossover design, we show that OT administration in ASD increases activity in brain regions important for perceiving social-emotional information. Further, OT enhances connectivity between nodes of the brain’s reward and socioemotional processing systems, and does so preferentially for social (versus nonsocial) stimuli. This effect is observed both while viewing coherent versus scrambled biological motion, and while listening to happy versus angry voices. Our findings suggest a mechanism by which intranasal OT may bolster social motivation—one that could, in future, be harnessed to augment behavioral treatments for ASD.

25 June 2019 in Journal of Psychopharmacology
Verified
Journal Article
Open access
PDF file
CPCharlotte Marie Pretzsch
Charlotte Marie Pretzsch
BVBogdan Voinescu
Bogdan Voinescu
MMMaria A Mendez
Maria A Mendez
RWRobert Wichers
Robert Wichers
LALaura Ajram
Laura Ajram
GMGráinne M McAlonan
Gráinne M McAlonan
Background: The potential benefits of cannabis and its major non-intoxicating component cannabidiol (CBD) are attracting attention, including as a potential treatment in neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural action of CBD, and its relevance to ASD, remains unclear. We and others have previously shown that response to drug challenge can be measured using functional magnetic resonance imaging (fMRI), but that pharmacological responsivity is atypical in ASD. Aims: We hypothesized that there would be a (different) fMRI response to CBD in ASD. Methods: To test this, task-free fMRI was acquired in 34 healthy men (half with ASD) following oral administration of 600 mg CBD or matched placebo (random order; double-blind administration). The ‘fractional amplitude of low-frequency fluctuations’ (fALFF) was measured across the whole brain, and, where CBD significantly altered fALFF, we tested if functional connectivity (FC) of those regions was also affected by CBD. Results: CBD significantly increased fALFF in the cerebellar vermis and the right fusiform gyrus. However, post-hoc within-group analyses revealed that this effect was primarily driven by the ASD group, with no significant change in controls. Within the ASD group only, CBD also significantly altered vermal FC with several of its subcortical (striatal) and cortical targets, but did not affect fusiform FC with other regions in either group. Conclusion: Our results suggest that, especially in ASD, CBD alters regional fALFF and FC in/between regions consistently implicated in ASD. Future studies should examine if this affects the complex behaviours these regions modulate.

5 January 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
QHQiyun Huang
Qiyun Huang
APAndreia C. Pereira
Andreia C. Pereira
HVHester Velthuis
Hester Velthuis
NWNichol M. L. Wong
Nichol M. L. Wong
CEClaire L. Ellis
Claire L. Ellis
GMGráinne M. McAlonan
Gráinne M. McAlonan
Differences in GABAergic function are critical to autistic visual sensory neurobiology and can be modulated by targeting GABAB.

1 July 2021 in Molecular Autism
Verified
Journal Article
Open access
PDF file
CPCharlotte Marie Pretzsch
Charlotte Marie Pretzsch
DFDorothea L. Floris
Dorothea L. Floris
BVBogdan Voinescu
Bogdan Voinescu
MEMalka Elsahib
Malka Elsahib
MMMaria A. Mendez
Maria A. Mendez
GMGráinne M. McAlonan
Gráinne M. McAlonan
Background: Autism spectrum disorder (ASD) has a high cost to affected individuals and society, but treatments for core symptoms are lacking. To expand intervention options, it is crucial to gain a better understanding of potential treatment targets, and their engagement, in the brain. For instance, the striatum (caudate, putamen, and nucleus accumbens) plays a central role during development and its (atypical) functional connectivity (FC) may contribute to multiple ASD symptoms. We have previously shown, in the adult autistic and neurotypical brain, the non-intoxicating cannabinoid cannabidivarin (CBDV) alters the balance of striatal ‘excitatory–inhibitory’ metabolites, which help regulate FC, but the effects of CBDV on (atypical) striatal FC are unknown.Methods: To examine this in a small pilot study, we acquired resting state functional magnetic resonance imaging data from 28 men (15 neurotypicals, 13 ASD) on two occasions in a repeated-measures, double-blind, placebo-controlled study. We then used a seed-based approach to (1) compare striatal FC between groups and (2) examine the effect of pharmacological probing (600 mg CBDV/matched placebo) on atypical striatal FC in ASD. Visits were separated by at least 13 days to allow for drug washout.Results: Compared to the neurotypicals, ASD individuals had lower FC between the ventral striatum and frontal and pericentral regions (which have been associated with emotion, motor, and vision processing). Further, they had higher intra-striatal FC and higher putamenal FC with temporal regions involved in speech and language. In ASD, CBDV reduced hyperconnectivity to the neurotypical level.Limitations: Our findings should be considered in light of several methodological aspects, in particular our participant group (restricted to male adults), which limits the generalizability of our findings to the wider and heterogeneous ASD population.Conclusion: In conclusion, here we show atypical striatal FC with regions commonly associated with ASD symptoms. We further provide preliminary proof of concept that, in the adult autistic brain, acute CBDV administration can modulate atypical striatal circuitry towards neurotypical function. Future studies are required to determine whether modulation of striatal FC is associated with a change in ASD symptoms.Trial registration: clinicaltrials.gov, Identifier: NCT03537950. Registered May 25th, 2018—Retrospectively registered,https://clinicaltrials.gov/ct2/show/NCT03537950?term=NCT03537950&draw=2&rank=1.